Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03233230 · ClinicalTrials.gov registry record · Phase 2
Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 390
- Enrollment target
NCT03233230 is a Phase 2 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 390 participants.
The verdict
NCT03233230, a Phase 2 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 390 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the efficacy, dose response, and safety of M52951 in participants with Rheumatoid Arthritis (RA), and to consider a dose to took forward into Phase III development.
Interventions
- DRUG Placebo
- DRUG M2591 25 mg QD
- DRUG M2951 75 mg QD
- DRUG M2951 50 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2017-09-18 |
| Est. Completion | 2019-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03233230
The ClinicalTrials.gov registry entry for NCT03233230 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03233230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03233230 about?
NCT03233230 is a clinical study titled "Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis". The purpose of this study was to determine the efficacy, dose response, and safety of M52951 in participants with Rheumatoid Arthritis (RA), and to consider a dose to took forward into Phase III development.
What is the current status of trial NCT03233230?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 390 participants. The study started on 2017-09-18. Estimated completion is 2019-09-23.
What interventions are being tested in trial NCT03233230?
The interventions under investigation include: Placebo (DRUG), M2591 25 mg QD (DRUG), M2951 75 mg QD (DRUG), M2951 50 mg BID (DRUG).
Who is sponsoring clinical trial NCT03233230?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.